POLB Stock Overview
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.095 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.04 |
| Beta | 0 |
| 1 Month Change | 31.94% |
| 3 Month Change | 43.94% |
| 1 Year Change | 22.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.63% |
Recent News & Updates
Shareholder Returns
| POLB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.4% | 0.4% | 1.8% |
| 1Y | 22.6% | 4.1% | -3.7% |
Return vs Industry: POLB exceeded the UK Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: POLB exceeded the UK Market which returned -3.1% over the past year.
Price Volatility
| POLB volatility | |
|---|---|
| POLB Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: POLB is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: POLB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 7 | Jeremy Skillington | https://www.poolbegpharma.com |
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
| POLB fundamental statistics | |
|---|---|
| Market Cap | UK£47.50m |
| Earnings (TTM) | -UK£3.11m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.3x
P/E RatioIs POLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLB income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.11m |
| Earnings | -UK£3.11m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0062 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did POLB perform over the long term?
See historical performance and comparison